期刊文献+

不同剂量倍他乐克治疗急性心肌梗死的疗效对比 被引量:4

下载PDF
导出
摘要 目的:观察对比不同剂量的倍他乐克对急性心梗的临床疗效。方法:将60例急性心梗患者随机分两组,在常规治疗的基础上,每组给予不同剂量的倍他乐克进行治疗,观察组使用12.5 mg的倍他乐克进行治疗,对照组则从12.5 mg的剂量开始,增加剂量直至25 mg的倍他乐克进行治疗,疗程4周,观察两组的疗效。结果:倍他乐克可缓解胸痛,对照组用药1周后心率变异率明显小于观察组,两组患者均无心律失常或心力衰竭加重而死亡者。结论:倍他乐克可抑制急性心梗时交感神经的兴奋和增加血液中儿茶酚胺浓度,减少心律失常的发生,适量的倍他乐克用于急性心梗治疗可提高疗效。
作者 刘伟光
出处 《吉林医学》 CAS 2012年第6期1224-1224,共1页 Jilin Medical Journal
  • 相关文献

参考文献1

二级参考文献9

  • 1Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association statistics committee and stroke statistics committee [J]. Circulation, 2007,115(5) :69-171.
  • 2Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-STelevation myocardial infarction-executive summary[J]. J Am Coll Cardiol, 2007,50 (8) : 652-726.
  • 3Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarctionexecutive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) [ J ]. Circulation, 2004,110(5 ) : 282- 292.
  • 4Smith SC, Feldman TE, Hirshfeld JW, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary inter-venfion: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCM Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention) [J]. Circulation,2006,113(7) : 166-286.
  • 5Levine GN, Berger PB, Cohen DJ, et al. Newer pharmacotherapy in patients undergoing percutaneous coronary interventions: a guide for pharmacists and other health care professionals expert opinion from the American Heart Association's Diagnostic and Interventional Catheterization Committee and Council on Clinical Cardiology, and the American College of Clinical Pharmacy' s Cardiology Practice Research Network [J]. Pharmacotherapy, 2006,26 ( 11 ) : 1537-1556.
  • 6Grines CL, Bonow RO, Casey DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, Ameri-can College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians [J]. Cireulation,2007,115(6) :813-818.
  • 7Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update[J]. J Am Coll Cardiol,2006,47(10): 2130-2139.
  • 8Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular disease: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)[J]. Eur Heart J,2007,28(1):88-136.
  • 9Krumholz HM, Anderson JL, Brooks NH, et al. ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-Elevation Myocardial Infarction)[J]. J Am Coll Cardiol, 2006, 47(1) :236-265.

共引文献1

同被引文献32

  • 1van de Werf F,Janssens I.,Brzostek T,et al. Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a speicific bradycardlae agent in patients with acute myocardial infarction receiving thrombolytic therapy[J]. J Am Coil Cardiol,1993,22(2) :407-416.
  • 2Kinlay S,Schwartz GG, Olsson AG, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study[J]. Circulation, 2004,110(4) : 386- 391.
  • 3Antman EM, Anbe DT, Armstrong PW, et al. ACC /AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the management of patients with acute myocardial infarction) [J]. J Am Coil Cardiol, 2004, 44 (3) :671-719.
  • 4Malmberg K,Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registr[J]. Circulation, 2000,102(9) : 1014-1019.
  • 5Herlitz J, Hjalmarson A, Holmberg S, et al. Effect of metoprolol on chest pain in acute myocardial infarction[J]. Br Heart J,1984,51(4) :438-444.
  • 6Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates:ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and the ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines[J]. J Am Coll Cardiol, 2009,54 (23) : 2205-2241.
  • 7Chen ZM,Pan HC,Chen YP,et al. Early intravenous then oral metoprolol in 45, 852 patients with acute myocardial infarction: randomised placebo-controlled trial [J]. Lancet, 2005,366(9497) : 1622-1632.
  • 8张海.不同剂量辛伐他汀治疗急性心肌梗死疗效观察[J].中南药学,2009,7(6):465-467. 被引量:4
  • 9段蕊.美托洛尔对急性心肌梗死患者心率变异性的影响[J].中国现代药物应用,2009,3(19):80-81. 被引量:2
  • 10无.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2010,38(8):675-690. 被引量:1974

引证文献4

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部